Nadim S. Jafri, MD; Colin W. Howden, MD
Potential Financial Conflicts of Interest:Consultancies: C.W. Howden (Meretek, TAP, Takeda, Santarus, and Novartis). Honoraria: C.W. Howden (AstraZeneca, Meretek, and Santarus). Grants received: C.W. Howden (AstraZeneca).
Jafri NS, Howden CW. Errors in a Meta-analysis of Treatments for Helicobacter pylori Infection. Ann Intern Med. 2008;149:686. doi: 10.7326/0003-4819-149-9-200811040-00015
Download citation file:
Published: Ann Intern Med. 2008;149(9):686.
We thank Dr. Gatta and colleagues for their comments. Our rationale for including the trial that had used a regimen of ranitidinebismuthcitrate (1) is given in our article. However, a sensitivity analysis had excluded that trial by examining only studies that had compared 10 days of sequential treatment with 7 days of triple therapy (Table 3). Inclusion or exclusion of that trial did not substantially alter our results.
Regarding the issue of clarithromycin-resistant strains in the study by De Francesco and colleagues (2), Gatta and colleagues are correct. We regret our error in the transcription of these data. The corrected analysis still demonstrates an advantage of sequential over triple therapy.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only